论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Liu B, Wu ZJ, Mo H, He JL, Lin X, Guan J, Wei CY, Yuan ZC
Received 9 June 2018
Accepted for publication 2 October 2018
Published 14 November 2018 Volume 2018:10 Pages 5685—5689
DOI https://doi.org/10.2147/CMAR.S176743
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Dr Rituraj Purohit
Background: The
objective of the study was to assess the safety and efficacy of microwave
ablation (MWA) for breast cancer thoracic metastasis.
Materials and methods: Twelve
patients in our institution with a single lesion of breast cancer thoracic
metastases received MWA and invasive spine surgery from August 2014 to November
2016. MWA was executed using the MWA system (2,450 MHz) at 40 W or 50 W with
thermometers to control the ablation end points. The pathology of thoracic
metastases was confirmed through intraoperative biopsy before ablation. The
postoperative complications were recorded. The patients were followed up at 1,
3 and 6 months with contrast-enhanced computed tomography and magnetic
resonance imaging to monitor for tumor recurrence.
Results: The
average duration of follow-up for breast cancer thoracic metastases patients
(mean age 52.7±8.4 years) was 10.2 months. The rate of postoperative main
complications was 8.3% (1/12). The recurrence rate was 16.6% (2/12) as
confirmed by persistent enhancement.
Conclusion: MWA may
be used as the adjuvant treatment for thoracic metastases of breast cancer.
Results showed that few significant complications and less local recurrence
occurred during the follow-up stage. Future research should aim at discovering
more about the time controls for microwave–tissue interaction and treatment
parameters before widespread use.
Keywords: breast
cancer, thoracic metastasis, microwave ablation, complication